董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Sangita Shah Chairperson of the Board 59 10.00万美元 未持股 2025-10-16
Michael Pruitt -- Interim Chief Executive Officer and Director -- 未披露 未持股 2025-10-16
Keith Johnson -- Independent Director -- 未披露 未持股 2025-10-16
Pyahm Samani Chairman 35 未披露 未持股 2025-10-16

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Robert Wild Chief Executive Officer, Intelligent Product Solutions, Inc 54 35.14万美元 未持股 2025-10-16
Kathleen Weisberg Principal Accounting Officer and Chief Financial Officer 54 6.45万美元 未持股 2025-10-16
Fred Sklenar Chief Executive Officer and President of Kablooe Inc 61 未披露 未持股 2025-10-16
Michael Pruitt -- Interim Chief Executive Officer and Director -- 未披露 未持股 2025-10-16

董事简历

中英对照 |  中文 |  英文
Sangita Shah

Sangita Shah,目前她除了担任Bilby PLC非执行董事长和Swindon Town Football Club的董事,她还是Odyssean Enterprises Limite(一个私人咨询和投资公司)d的所有人以及董事。她也是Global Reach Technology(一个WiF快速通道中小企业)董事会顾问和Zypha Technologies Inc的非执行董事。


Sangita Shah currently serves as director and owner of Odyssean Enterprises Limited, a private advisory and investment company, in addition to serving as non-executive chairman of Bilby PLC and non-executive chairman of RA International PLC. Ms. Shah is also a board advisor to Global Reach Technology, a Fast Track WiFi company. Ms. Shah previously worked in seed/mezzanine financing and strategic investments within the environmental and technology sectors following a number of senior roles held at KPMG and Ernst & Young.
Sangita Shah,目前她除了担任Bilby PLC非执行董事长和Swindon Town Football Club的董事,她还是Odyssean Enterprises Limite(一个私人咨询和投资公司)d的所有人以及董事。她也是Global Reach Technology(一个WiF快速通道中小企业)董事会顾问和Zypha Technologies Inc的非执行董事。
Sangita Shah currently serves as director and owner of Odyssean Enterprises Limited, a private advisory and investment company, in addition to serving as non-executive chairman of Bilby PLC and non-executive chairman of RA International PLC. Ms. Shah is also a board advisor to Global Reach Technology, a Fast Track WiFi company. Ms. Shah previously worked in seed/mezzanine financing and strategic investments within the environmental and technology sectors following a number of senior roles held at KPMG and Ernst & Young.
Michael Pruitt
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Keith Johnson
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Pyahm Samani

Pyahm Samani,于2017年5月创立了Multicoin Capital,是此次私募的三位主要投资者之一,自成立以来一直担任该公司的管理合伙人之一。作为管理合伙人,他领导投资团队、寻找投资、谈判交易,并与投资组合创始人合作。自2022年以来,他就影响该行业的关键监管问题与国会议员和政府直接合作。


Pyahm Samani,founded Multicoin Capital, one of the three lead investors in the Private Placement, in May 2017 and has served as one of the firm's Managing Partners since its founding. As Managing Partner, he leads the investment team, sources investments, negotiates transactions, and collaborates with portfolio founders. Since 2022 he has worked directly with members of Congress and the administration on key regulatory issues affecting the industry.
Pyahm Samani,于2017年5月创立了Multicoin Capital,是此次私募的三位主要投资者之一,自成立以来一直担任该公司的管理合伙人之一。作为管理合伙人,他领导投资团队、寻找投资、谈判交易,并与投资组合创始人合作。自2022年以来,他就影响该行业的关键监管问题与国会议员和政府直接合作。
Pyahm Samani,founded Multicoin Capital, one of the three lead investors in the Private Placement, in May 2017 and has served as one of the firm's Managing Partners since its founding. As Managing Partner, he leads the investment team, sources investments, negotiates transactions, and collaborates with portfolio founders. Since 2022 he has worked directly with members of Congress and the administration on key regulatory issues affecting the industry.

高管简历

中英对照 |  中文 |  英文
Robert Wild

Robert Wild,在加入Ignyta之前,他于2010年8月至2014年8月在礼来公司担任肿瘤学研究和药物发现首席科学官。在加入礼来公司之前,Wild博士曾于2006年1月至2010年7月在OSI Pharmaceuticals,Inc.担任越来越重要的职务,包括在体内药理学、分子成像和研究DMPK领域的肿瘤学研究高级总监。在任职OSI之前,Wild博士曾在百时美施贵宝工作了四年多,此前他还曾在SUGEN,Inc.工作。Wild博士拥有明尼苏达大学的药理学博士学位和生物化学学士学位。


Robert Wild joined in September 2014. Prior to joining Ignyta, Dr. Wild was Chief Scientific Officer, Oncology Research, Drug Discovery at Eli Lilly & Company, a position he held from August 2010 to August 2014. Prior to Lilly, Dr. Wild held positions of increasing responsibility from January 2006 to July 2010 at OSI Pharmaceuticals, Inc., including Senior Director, Oncology Research, In Vivo Pharmacology, Molecular Imaging & Research DMPK. Before his tenure at OSI, Dr. Wild spent more than four years at Bristol-Myers Squibb, and he also previously worked at SUGEN, Inc. Dr. Wild holds both a Ph.D. in pharmacology and a B.S. in biochemistry from the University of Minnesota.
Robert Wild,在加入Ignyta之前,他于2010年8月至2014年8月在礼来公司担任肿瘤学研究和药物发现首席科学官。在加入礼来公司之前,Wild博士曾于2006年1月至2010年7月在OSI Pharmaceuticals,Inc.担任越来越重要的职务,包括在体内药理学、分子成像和研究DMPK领域的肿瘤学研究高级总监。在任职OSI之前,Wild博士曾在百时美施贵宝工作了四年多,此前他还曾在SUGEN,Inc.工作。Wild博士拥有明尼苏达大学的药理学博士学位和生物化学学士学位。
Robert Wild joined in September 2014. Prior to joining Ignyta, Dr. Wild was Chief Scientific Officer, Oncology Research, Drug Discovery at Eli Lilly & Company, a position he held from August 2010 to August 2014. Prior to Lilly, Dr. Wild held positions of increasing responsibility from January 2006 to July 2010 at OSI Pharmaceuticals, Inc., including Senior Director, Oncology Research, In Vivo Pharmacology, Molecular Imaging & Research DMPK. Before his tenure at OSI, Dr. Wild spent more than four years at Bristol-Myers Squibb, and he also previously worked at SUGEN, Inc. Dr. Wild holds both a Ph.D. in pharmacology and a B.S. in biochemistry from the University of Minnesota.
Kathleen Weisberg

Kathleen Weisberg,被任命为公司首席财务官,自2023年7月1日起生效。在被任命为首席财务官之前,Weisberg女士于2020年6月至2023年6月期间担任公司的公司控制人。2017年6月至2020年6月,Weisberg女士担任爬行动物和水族箱产品公司Jungle Bob Enterprises,Inc.的财务总监。2003年12月至2010年3月,Weisberg女士在WW International,Inc.(前身为Weight Watchers International,Inc.)担任SEC报告高级经理。1998年10月至2003年11月,Weisberg女士在移动数据捕获和传输设备制造商和供应商Symbol Technologies, Inc.担任高级审计师和公司会计经理。从1992年1月至1998年10月,Weisberg女士在安永会计师事务所担任审计员。


Kathleen Weisberg,was appointed the Company's Chief Financial Officer effective July 1, 2023. Prior to her appointment as Chief Financial Officer, Ms. Weisberg served as the Company's Corporate Controller from June 2020 to June 2023. From June 2017 to June 2020, Ms. Weisberg served as the Controller for Jungle Bob Enterprises, Inc., a reptile and aquarium product company. From December 2003 to March 2010, Ms. Weisberg served as the Senior Manager for SEC Reporting at WW International, Inc., formerly Weight Watchers International, Inc. From October 1998 to November 2003, Ms. Weisberg served as Senior Auditor and Corporate Accounting Manager for Symbol Technologies, Inc., a manufacturer and supplier of mobile data capture and delivery equipment. From January 1992 to October 1998, Ms. Weisberg was an auditor at Ernst & Young LLP.
Kathleen Weisberg,被任命为公司首席财务官,自2023年7月1日起生效。在被任命为首席财务官之前,Weisberg女士于2020年6月至2023年6月期间担任公司的公司控制人。2017年6月至2020年6月,Weisberg女士担任爬行动物和水族箱产品公司Jungle Bob Enterprises,Inc.的财务总监。2003年12月至2010年3月,Weisberg女士在WW International,Inc.(前身为Weight Watchers International,Inc.)担任SEC报告高级经理。1998年10月至2003年11月,Weisberg女士在移动数据捕获和传输设备制造商和供应商Symbol Technologies, Inc.担任高级审计师和公司会计经理。从1992年1月至1998年10月,Weisberg女士在安永会计师事务所担任审计员。
Kathleen Weisberg,was appointed the Company's Chief Financial Officer effective July 1, 2023. Prior to her appointment as Chief Financial Officer, Ms. Weisberg served as the Company's Corporate Controller from June 2020 to June 2023. From June 2017 to June 2020, Ms. Weisberg served as the Controller for Jungle Bob Enterprises, Inc., a reptile and aquarium product company. From December 2003 to March 2010, Ms. Weisberg served as the Senior Manager for SEC Reporting at WW International, Inc., formerly Weight Watchers International, Inc. From October 1998 to November 2003, Ms. Weisberg served as Senior Auditor and Corporate Accounting Manager for Symbol Technologies, Inc., a manufacturer and supplier of mobile data capture and delivery equipment. From January 1992 to October 1998, Ms. Weisberg was an auditor at Ernst & Young LLP.
Fred Sklenar

Fred Sklenar,自2024年1月起担任Kabloee,Inc.项目计划总监。在此之前,Sklenar先生是Abstrategy Design的首席运营官,这是他于1991年创立的一家设计公司。


Fred Sklenar,has been the Director of Project Plans of Kabloee, Inc. since January 2024. Prior to that, Mr. Sklenar was the Chief Operating Officer of Abstrategy Design, a design firm he founded in 1991.
Fred Sklenar,自2024年1月起担任Kabloee,Inc.项目计划总监。在此之前,Sklenar先生是Abstrategy Design的首席运营官,这是他于1991年创立的一家设计公司。
Fred Sklenar,has been the Director of Project Plans of Kabloee, Inc. since January 2024. Prior to that, Mr. Sklenar was the Chief Operating Officer of Abstrategy Design, a design firm he founded in 1991.
Michael Pruitt
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介